Displaying publications 41 - 52 of 52 in total

Abstract:
Sort:
  1. Kanesen D, Zakaria Z, Ch'ng ES, Nandrajog P, Kandasamy R
    ANZ J Surg, 2019 03;89(3):261-264.
    PMID: 28513108 DOI: 10.1111/ans.14040
  2. Kadir F, Soe MZ, Hayati F, Fahmy EHAM, Aung T
    ANZ J Surg, 2021 10;91(10):2225.
    PMID: 34665502 DOI: 10.1111/ans.17061
  3. Mah JJ, Chuah JA, Hayati F
    ANZ J Surg, 2021 Nov;91(11):2536-2538.
    PMID: 33713534 DOI: 10.1111/ans.16750
  4. Mat Lazim N, Elliott M, Wykes J, Clark J
    ANZ J Surg, 2021 Dec;91(12):2617-2623.
    PMID: 33634950 DOI: 10.1111/ans.16622
    Historically, patients with head and neck squamous cell carcinoma (HNSCC) with distant metastases were regarded as palliative. Oligometastasis (OM) refers to patients with a limited number of distant metastatic deposits. Treatment of patients with OMs has been reported in patients with lung, colon, breast, prostate and brain malignancies. Selected patients with oligometastatic HNSCC have a higher probability of durable disease control and cure and these patients should be treated aggressively. Treatment options for patients with HNSCC OMs include single or combinations of the three arms of cancer treatment, that is surgery, radiotherapy and chemotherapy/immunotherapy. To date, there are limited studies reporting the management of OM with head and neck malignancy. This review will give insights into the management of OMs in HNSCC.
Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links